Humatrope

Humatrope is a prescription injectable solution that contains the recombinant human growth hormone somatropin. It is supplied in a sterile liquid form for subcutaneous administration and is marketed in the European Union. The product provides a standardized dose of somatropin, enabling clinicians to replace deficient endogenous growth hormone in patients with specific endocrine disorders. Humatrope is classified as a growth hormone therapy for treatment in clinical practice.

Humatrope is indicated for several endocrine conditions where growth hormone replacement is required.

- Growth hormone deficiency in children, to support normal linear growth - Growth hormone deficiency in adults, to improve body composition and metabolic profile - Turner syndrome-associated short stature, to increase final adult height - Chronic renal insufficiency with growth failure, to promote growth when renal function is compromised - Prader‑Willi syndrome related growth impairment, as part of a comprehensive management plan - Idiopathic short stature in pediatric patients, when other causes have been excluded

Adverse reactions to Humatrope vary in frequency and severity.

Common: - Mild injection‑site reactions such as pain, redness, swelling, or bruising that usually resolve within a few days - Transient headache, dizziness, or nausea that are generally self‑limited and do not require intervention - Temporary peripheral edema, particularly in the lower extremities, which may be intermittent and mild

Serious: - Intracranial hypertension presenting with persistent headache, nausea, vomiting, or visual disturbances, potentially leading to papilledema - New‑onset diabetes mellitus or significant worsening of existing glucose intolerance, requiring monitoring of blood sugar levels - Slipped capital femoral epiphysis, a painful hip condition in adolescents that may need orthopedic evaluation - Severe allergic reactions, including rash, urticaria, angioedema, or anaphylaxis, which demand immediate medical attention - Increased intracranial pressure causing visual field loss, papilledema, or other neurologic signs

Clinicians should consider several precautions before initiating Humatrope therapy.

- Not indicated for patients with active malignancy or a history of cancer due to potential tumor growth stimulation - Caution in individuals with intracranial hypertension, as growth hormone may exacerbate the condition - Monitor blood glucose regularly in patients with diabetes or risk factors for impaired glucose tolerance - Assess thyroid function before and during treatment, since hypothyroidism can blunt response - Evaluate for signs of slipped capital femoral epiphysis in growing children, especially during rapid growth phases - Use with care in patients with severe renal or hepatic impairment, adjusting dose as recommended

Humatrope may interact with certain medications or substances, influencing its efficacy or safety profile.

Avoid: - Concomitant use of high‑dose glucocorticoids, which can antagonize the anabolic actions of growth hormone and diminish treatment efficacy. - Simultaneous administration of insulin‑like growth factor‑1 (IGF‑1) therapy, which may potentiate hypoglycemia risk due to additive insulin‑like effects.

Use with caution: - Oral estrogen therapy, because estrogen can reduce the peripheral conversion of growth hormone to IGF‑1, lowering the expected growth response. - Antidiabetic agents, since Humatrope may alter glucose homeostasis and require closer monitoring of blood‑sugar levels. - Medications known to increase intracranial pressure, such as certain corticosteroids, which could exacerbate the risk of intracranial hypertension when combined with growth hormone.